The company manufactures and sells industrial explosives, detonating fuses, and cast boosters primarily for the mining, infrastructure, and defense sectors.
The business benefits from high regulatory barriers to entry due to PESO licensing requirements and safety protocols, but the low net margins (2.7% average) and high capital intensity suggest a lack of durable pricing power or a cost-scale advantage.
Earnings and IPO proceeds are being aggressively reinvested into capacity expansion for detonators and backward integration to secure raw materials. While revenue growth is high, the low net margins suggest that the reinvested capital is not yet yielding high-quality bottom-line returns.
The aggressive capacity expansion funded by the IPO proved to be a value-destructive trap as the company scaled into a low-margin commodity cycle. The razor-thin 2.7% net margins provided no buffer when raw material costs spiked, and the lack of pricing power meant the company could not pass costs to customers. Meanwhile, the governance red flags that were ignored at the outset—specifically the auditor resignation and related-party dealings—manifested as a full-blown accounting scandal, revealing that the high EPS growth was a mirage of aggressive revenue recognition and non-arm's length transactions.
RichFakir rates Beezaasan Explotech Ltd's business quality as mediocre — 45/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Beezaasan Explotech Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Beezaasan Explotech Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Beezaasan Explotech Ltd's fair value is about ₹80 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →